Faes Farma FAE.MC
Faes Farma is a Spanish pharmaceutical company specializing in the development, manufacturing, and marketing of prescription drugs, mainly in allergology, dermatology, and central nervous system, with a business model based on proprietary innovation and international expansion. Faes Farma shows 24% revenue growth and a forward P/E of 13.49, suggesting an attractive valuation, although cash conversion (15.53%) and ROE (11.22%) are weak, limiting the quality of its moat.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Faes Farma is a Spanish pharmaceutical company specializing in the development, manufacturing, and marketing of prescription drugs, mainly in allergology, dermatology, and central nervous system, with a business model based on proprietary innovation and international expansion. Faes Farma shows 24% revenue growth and a forward P/E of 13.49, suggesting an attractive valuation, although cash conversion (15.53%) and ROE (11.22%) are weak, limiting the quality of its moat.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.7 |
| Quality / Moat | 5.2 |
| Valuation | 5.8 |
| Growth | 7.3 |
| Dividend | 7.4 |
| Momentum | 4.5 |
| Risk & Context | 7.5 |
OVERALL SCORE: 6.2/10
Context and risks
Elevated governance risk in Spain and regulatory exposure of the pharmaceutical sector to pricing pressure. However, the company has no direct exposure to current macro factors (oil, rates, geopolitics) that materially affect its business.
News considered in the analysis
- Faes Farma (BME:FAE) Following Strong Half Year Earnings Still Looks Undervalued — Análisis positivo tras resultados semestrales sólidos, refuerza la percepción de infravaloración pero no aporta información nueva material.
- European Penny Stocks To Watch In May 2026 — Listículo genérico sin información específica sobre la empresa.
- 3 European Dividend Stocks Yielding Over 3.1% — Listículo genérico de dividendos, sin información nueva.
- European Penny Stocks To Watch In December 2025 — Listículo desactualizado, sin relevancia.
- 3 European Dividend Stocks Yielding Up To 9.3% — Listículo genérico de dividendos, sin información nueva.
Verdict: Hold; valuation is reasonable and growth is solid, but cash generation and return on capital need to improve to justify a more aggressive position.
Main risk: Weak cash conversion (15.53%) and regulatory risk in the Spanish pharmaceutical sector, with potential pricing pressure, are the main risks for Faes Farma.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →